Principal Financial Group Inc. Buys New Holdings in BIOVERATIV INC (BIVV)

Principal Financial Group Inc. bought a new stake in BIOVERATIV INC (NASDAQ:BIVV) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 553,189 shares of the biotechnology company’s stock, valued at approximately $31,571,000. Principal Financial Group Inc. owned approximately 0.51% of BIOVERATIV INC as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. TCI Wealth Advisors Inc. purchased a new stake in shares of BIOVERATIV INC in the third quarter valued at about $186,000. Canada Pension Plan Investment Board purchased a new stake in shares of BIOVERATIV INC in the third quarter valued at about $194,000. Essex Investment Management Co. LLC purchased a new stake in shares of BIOVERATIV INC in the third quarter valued at about $238,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new stake in shares of BIOVERATIV INC in the third quarter valued at about $242,000. Finally, Traynor Capital Management Inc. purchased a new stake in shares of BIOVERATIV INC in the third quarter valued at about $244,000. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Shares of BIOVERATIV INC (NASDAQ:BIVV) opened at $56.11 on Friday. BIOVERATIV INC has a fifty-two week low of $40.00 and a fifty-two week high of $64.41.

BIOVERATIV INC (NASDAQ:BIVV) last announced its quarterly earnings results on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.25. The company had revenue of $291.60 million for the quarter, compared to the consensus estimate of $285.45 million. BIOVERATIV INC had a net margin of 40.44% and a return on equity of 69.03%. The company’s revenue for the quarter was up 27.2% compared to the same quarter last year. research analysts forecast that BIOVERATIV INC will post 2.45 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Principal Financial Group Inc. Buys New Holdings in BIOVERATIV INC (BIVV)” was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/11/19/principal-financial-group-inc-buys-new-holdings-in-bioverativ-inc-bivv.html.

A number of analysts recently commented on BIVV shares. Jefferies Group LLC reissued a “buy” rating and set a $70.00 price objective (up previously from $67.00) on shares of BIOVERATIV INC in a report on Wednesday, August 9th. Cowen and Company reissued a “buy” rating and set a $80.00 price objective on shares of BIOVERATIV INC in a report on Friday, August 4th. Argus raised shares of BIOVERATIV INC from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a report on Wednesday, September 20th. Zacks Investment Research downgraded shares of BIOVERATIV INC from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 1st. Finally, Evercore ISI started coverage on shares of BIOVERATIV INC in a report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $61.73.

BIOVERATIV INC Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Institutional Ownership by Quarter for BIOVERATIV INC (NASDAQ:BIVV)

Receive News & Ratings for BIOVERATIV INC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOVERATIV INC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply